Home › NDC Lookup › RxCUI directory › RxCUI 1657361

0.5 ML palivizumab 100 MG/ML Injection — RxCUI 1657361

RxNorm drug concept · Semantic clinical drug
RxCUI 1657361 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1657361
Official name0.5 ML palivizumab 100 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aspalivizumab 50 MG per 0.5 ML Injection; palivizumab 50 MG in 0.5 ML Injection
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)1,742 prescriptions · 15 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Palivizumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Synagis protects high-risk babies and young children from RSV — respiratory syncytial virus — which can cause serious lung infections like pneumonia and bronchiolitis. For healthy...
  • What exactly is Synagis protecting my baby from?
  • Unfortunately, no. Synagis is approved only for preventing RSV infection, not for treating one that's already started. The safety and effectiveness of Synagis as a treatment haven'...
  • My baby already caught RSV — can Synagis help treat it?
📖 Read our full Palivizumab Injection guide →

🕸️ Concept Web — How 0.5 ML palivizumab 100 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 0.5 ML palivizumab 100 MG/ML Injection RxCUI 1657361

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Palivizumab 194279
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Synagis 220141
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Palivizumab Injection 1657340
    • Palivizumab Injectable Product 1160711
    • Palivizumab Injection [Synagis] 1657342
    • Synagis Injectable Product 1186044
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Palivizumab 100 MG/ML SCDC · 330081
  • Palivizumab Injection SCDF · 1657340
  • Palivizumab Injectable Product SCDG · 1160711

Brand-Name Concepts

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 1657361 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
66658-0230-01 .5 mL in 1 VIAL, SINGLE-DOSE (66658-230-01) Synagis Swedish Orphan Biovitrum AB (publ) 2005-09-28
66658-0231-01 1 mL in 1 VIAL, SINGLE-DOSE (66658-231-01) Synagis Swedish Orphan Biovitrum AB (publ) 2005-09-28
Observed labelers: Swedish Orphan Biovitrum AB (publ) (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.